WHO downgrades status of oseltamivir

  title={WHO downgrades status of oseltamivir},
  author={Mark H. Ebell},
  journal={British Medical Journal},
  • M. Ebell
  • Published 2017
  • Medicine
  • British Medical Journal
Important lessons from the Tamiflu story 
Covid-19: What now for remdesivir?
The spectre of past pandemics looms large over remdesivir, one of the first drug treatments for covid-19. With a WHO trial finding little benefit, Jeremy Hsu asks if the expensive drug is justExpand
Repurposing drugs targeting the P2X7 receptor to limit hyperinflammation and disease during influenza virus infection
It is demonstrated that the NLRP3 inflammasome plays time‐dependent roles during severe IAV infection with early protective responses and later dysregulation leading to excessive inflammation, contributing to disease severity. Expand
Evidencias para el diagnóstico y tratamiento de influenza en adultos
Treatment with antiviral therapy based on a neuraminidase inhibitor may shorten the duration of the symptoms, in addition to reducing the complications particularly in immunocompromised individuals or at high risk of complications. Expand
The REMAP-CAP (Randomized Embedded Multifactorial Adaptive Platform for Community-acquired Pneumonia) Study. Rationale and Design
A large, international trial that combines features of adaptive platform trials with pragmatic point-of-care trials to determine best treatment strategies for patients admitted to an intensive care unit with severe community-acquired pneumonia is presented. Expand
Clinical characteristics, evolution, and treatment‐related risk factors for mortality among immunosuppressed patients with influenza A (H1N1) virus admitted to the intensive care unit
Immunocompromised individuals with influenza A (H1N1) admitted to the ICU have a poor outcome, and the use of corticosteroids is strongly discouraged. Expand
Pacientes con gripe por el virus influenza A (H1N1)pdm09 ingresados en la UCI. Impacto de las recomendaciones de la SEMICYUC
Las recomendaciones de the SEMICYUC del ano 2012 han mejorado el diagnostico precoz y el uso of corticoides, y queda por mejORar el retraso en el tratamiento, the tasa of vacunacion y the utilizacion of the VMNI. Expand
US purchases world stocks of remdesivir: why the rest of the world should be glad to be at the back of the queue
The remdesivir story may actually be good news for the rest of the world, argues James M Brophy
TANKing Influenza A Virus in the Lung.
  • S. Rosli, M. Tate
  • Medicine, Biology
  • American journal of respiratory cell and molecular biology
  • 2019
Patients with influenza A (H1N1)pdm09 admitted to the ICU. Impact of the recommendations of the SEMICYUC
The management of patients with severe influenza A (H1N1) has changed over the years, though without changes in mortality, and the recommendations of the SEMICYUC (2012) have allowed earlier diagnosis and improved corticosteroid use. Expand


Neuraminidase inhibitors—the story behind the Cochrane review
  • P. Doshi
  • Medicine
  • BMJ : British Medical Journal
  • 2009
Although billions have been spent on oseltamivir in the face of pandemic influenza, the team updating the Cochrane review of neuraminidase inhibitors in healthy adults found that the public evidenceExpand
Tamiflu: “a nice little earner”
  • A. Jack
  • Medicine
  • BMJ : British Medical Journal
  • 2014
Is the story of oseltamivir, and similar antiviral drugs, a classic one of big pharma greed? Andrew Jack finds a more nuanced reality
Multisystem failure: the story of anti-influenza drugs
What the new systematic review found and how a series of failures meant that decisions about these drugs were made without the full evidence are explained. Expand
What can we learn from observational studies of oseltamivir to treat influenza in healthy adults?
It was found studies of oseltamivir identified by Roche were of limited value, according to Nick Freemantle and Mel Calvert. Expand
Efficacy and Safety of the Oral Neuraminidase Inhibitor Oseltamivir in Treating Acute Influenza
The data suggest that oral oseltamivir treatment reduces the duration and severity of acute influenza in healthy adults and may decrease the incidence of secondary complications. Expand
Oseltamivir for influenza in adults and children: systematic review of clinical study reports and summary of regulatory comments
The effect on unverified pneumonia in children and for prophylaxis was not significant and there was no significant reduction in risk of unverified bronchitis, otitis media, sinusitis, or any complication classified as serious or that led to study withdrawal. Expand
Effectiveness of oseltamivir in adults: a meta-analysis of published and unpublished clinical trials.
There is no evidence that oseltamivir reduces the likelihood of hospitalization, pneumonia or the combined outcome of pneumonia, otitis media and sinusitis in the ITT population. Expand
Neuraminidase inhibitors for preventing and treating influenza in healthy adults: systematic review and meta-analysis
The remaining evidence suggests oseltamivir did not reduce influenza related lower respiratory tract complications and neuraminidase inhibitors have modest effectiveness against the symptoms of influenza in otherwise healthy adults. Expand
Performance of six influenza rapid tests in detecting human influenza in clinical specimens.
A head-to-head comparison for the detection of seasonal influenza types A and B, compared to laboratory-based tests found sensitivity was considerably lower than that seen for influenza A, although the number of specimens containing influenza B viruses was low. Expand
The missing data that cost $20bn
  • K. Abbasi
  • Medicine
  • BMJ : British Medical Journal
  • 2014
From trusting the literature, researchers, and companies, Jefferson moved to a position of deep scepticism, decisions on purchasing, stockpiling, and using the drugs were based on a slim and skewed representation of the total evidence base. Expand